Top

Inflammation Research

Published in:

01-03-2020 | Atopic Dermatitis | Original Research Paper

Igalan from Inula helenium (L.) suppresses the atopic dermatitis-like response in stimulated HaCaT keratinocytes via JAK/STAT3 signaling

Authors: Thien T. P. Dao, Kwangho Song, Jee Young Kim, Yeong Shik Kim

Published in: Inflammation Research | Issue 3/2020

Abstract

Objective

This study aimed to evaluate the protective effect of igalan, a sesquiterpene lactone isolated from Inula helenium (L.), on inhibiting inflammation, regulating the epidermal differentiation gene expression, and reactive oxygen species scavenging in atopic dermatitis (AD)-like inflammatory keratinocytes.

Methods

HaCaT human keratinocytes were treated with igalan at indicated concentrations before being activated by a combination of TNF-α and IFN-γ or IL-4 representative for T-helper 1 and T-helper 2 cell cytokines, which are associated with AD pathogenesis.

Results

By inhibiting the NF-κB pathway as well as the STAT activation, igalan could downregulate several marker inflammatory genes in AD, such as TARC/CCL17, MDC/CCL22, and RANTES/CCL5. In contrast, igalan, acting as JAK inhibitor, could promote the mRNA expression levels of the genes FLG, LOR, KRT10, and DSC1, which encode for essential proteins responsible for keratinocyte differentiation, by inhibiting STAT3 signaling. Furthermore, igalan exerts its antioxidant effect through activating the Nrf2 pathway, triggering the expression of some enzymes that contribute to preventing intracellular ROS generation during inflammation.

Conclusion

These findings indicate that igalan, via suppressing JAK/STAT3 signaling, could impair the production of pro-inflammatory chemokines and enhance expression levels of several genes involved in keratinocyte differentiation in AD-like stimulated keratinocytes.

Available only for authorised users

Dainichi T, Hanakawa S, Kabashima K. Classification of inflammatory skin diseases: a proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity. J Dermatol Sci. 2014;76(2):81–9. https://doi.org/10.1016/j.jdermsci.2014.08.010.CrossRefPubMed

Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T, Kadono T. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403. https://doi.org/10.1016/j.alit.2016.12.002.CrossRefPubMed

Wong ITY, Tsuyuki RT, Cresswell-Melville A, Doiron P, Drucker AM. Guidelines for the management of atopic dermatitis (eczema) for pharmacists. Can Pharm J (Ott). 2017;150(5):285–97. https://doi.org/10.1177/1715163517710958.CrossRefPubMedCentral

Murota H, Takeuchi S, Sugaya M, Tanioka M, Onozuka D, Hagihara A, Saeki H, Imafuku S, Abe M, Shintani Y, Kaneko S, Masuda K, Hiragun T, Inomata N, Kitami Y, Tsunemi Y, Abe S, Kobayashi M, Morisky DE, Furue M, Katoh N. Characterization of socioeconomic status of Japanese patients with atopic dermatitis showing poor medical adherence and reasons for drug discontinuation. J Dermatol Sci. 2015;79(3):279–87. https://doi.org/10.1016/j.jdermsci.2015.05.010.CrossRefPubMed

Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. https://doi.org/10.1016/j.jaad.2005.01.010.CrossRefPubMed

Saaf AM, Tengvall-Linder M, Chang HY, Adler AS, Wahlgren CF, Scheynius A, Nordenskjold M, Bradley M. Global expression profiling in atopic eczema reveals reciprocal expression of inflammatory and lipid genes. PLoS ONE ONE. 2008. https://doi.org/10.1371/journal.pone.0004017.CrossRef

Giridharan S, Srinivasan M. Mechanisms of NF-kappaB p65 and strategies for therapeutic manipulation. J Inflamm Res. 2018;11:407–19. https://doi.org/10.2147/JIR.S140188.CrossRefPubMedPubMedCentral

Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013. https://doi.org/10.4161/jkst.24137.CrossRefPubMedPubMedCentral

Klonowska J, Gleń J, Nowicki RJ, Trzeciak M. New cytokines in the pathogenesis of atopic dermatitis—new therapeutic targets. Int J Mol Sci. 2018;19:3086.CrossRef

10.

Omata N, Tsukahara H, Ito S, Ohshima Y, Yasutomi M, Yamada A, Jiang M, Hiraoka M, Nambu M, Deguchi Y, Mayumi M. Increased oxidative stress in childhood atopic dermatitis. Life Sci. 2001;69(2):223–8.CrossRef

11.

Nakai K, Yoneda K, Maeda R, Munehiro A, Fujita N, Yokoi I, Moriue J, Moriue T, Kosaka H, Kubota Y. Urinary biomarker of oxidative stress in patients with psoriasis vulgaris and atopic dermatitis. J Eur Acad Dermatol Venereol. 2009;23(12):1405–8.CrossRef

12.

Lee KM, Shin JM, Chun J, Song K, Nho CW, Kim YS. Igalan induces detoxifying enzymes mediated by the Nrf2 pathway in HepG2 cells. J Biochem Mol Toxicol. 2019. https://doi.org/10.1002/jbt.22297.CrossRefPubMed

13.

Moon KY, Hahn BS, Lee J, Kim YS. A cell-based assay system for monitoring NF-kappaB activity in human HaCat transfectant cells. Anal Biochem. 2001;292(1):17–211. https://doi.org/10.1006/abio.2001.5059.CrossRefPubMed

14.

Chun J, Choi RJ, Khan S, Lee DS, Kim YC, Nam YJ, Lee DU, Kim YS. Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-kappaB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells. Int Immunopharmacol. 2012;14(4):375–83. https://doi.org/10.1016/j.intimp.2012.08.011.CrossRefPubMed

15.

O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–50. https://doi.org/10.1016/j.immuni.2012.03.014.CrossRefPubMedPubMedCentral

16.

Jeong SJ, Lim HS, Seo CS, Jin SE, Yoo SR, Lee N, Shin HK. Anti-inflammatory actions of herbal formula Gyejibokryeong-hwan regulated by inhibiting chemokine production and STAT1 activation in HaCaT cells. Biol Pharm Bull. 2015;38(3):425–34. https://doi.org/10.1248/bpb.b14-00660.CrossRefPubMed

17.

Horiuchi Y, Bae SJ, Katayama I. Overexpression of the suppressor of cytokine signalling 3 (SOCS3) in severe atopic dermatitis. Clin Exp Dermatol. 2006;31(1):100–4. https://doi.org/10.1111/j.1365-2230.2005.01979.x.CrossRefPubMed

18.

David M, Ford D, Bertoglio J, Maizel AL, Pierre J. Induction of the IL-13 receptor alpha2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways. Oncogene. 2001;20(46):6660–8. https://doi.org/10.1038/sj.onc.1204629.CrossRefPubMed

19.

Sun Y, Lu Q, He L, Shu Y, Zhang S, Tan S, Tang L. Active fragment of Veronica ciliata Fisch. attenuates t-BHP-induced oxidative stress injury in HepG2 cells through antioxidant and antiapoptosis activities. Oxid Med Cell Longev. 2017. https://doi.org/10.1155/2017/4727151.CrossRefPubMedPubMedCentral

20.

Morgan MJ, Liu Z-g. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2010;21:103. https://doi.org/10.1038/cr.2010.178.CrossRefPubMedPubMedCentral

21.

Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Investig. 2004;113(5):651–7. https://doi.org/10.1172/JCI21060.CrossRefPubMed

22.

Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, El Ghalbzouri A, Bouwstra JA. TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Investig Dermatol. 2014;134(7):1941–50. https://doi.org/10.1038/jid.2014.83.CrossRefPubMed

23.

De Vuyst E, Salmon M, Evrard C, de Rouvroit CL, Poumay Y. Atopic dermatitis studies through in vitro models. Front Med. 2017. https://doi.org/10.3389/fmed.2017.00119.CrossRef

24.

Lim HS, Yo SR, Lee MY, Seo CS, Shin HK, Jeong SJ. Potential inhibitory effects of the traditional herbal prescription Hyangso-san against skin inflammation via inhibition of chemokine production and inactivation of STAT1 in HaCaT keratinocytes. Mol Med Rep. 2018;17(2):2515–22. https://doi.org/10.3892/mmr.2017.8172.CrossRefPubMed

25.

Gluck J, Rogala B. Chemokine RANTES in atopic dermatitis. Arch Immunol Ther Exp (Warsz). 1999;47(6):367–72.PubMed

26.

Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatol Sci. 2004;34(3):201–8. https://doi.org/10.1016/j.jdermsci.2004.01.001.CrossRefPubMed

27.

Thijs JL, de Bruin-Weller MS, Hijnen D. Current and future biomarkers in atopic dermatitis. Immunol Allergy Clin North Am. 2017;37(1):51–61. https://doi.org/10.1016/j.iac.2016.08.008.CrossRefPubMed

28.

Leyva-Castillo JM, Hener P, Jiang H, Li M. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J Invest Dermatol. 2013;133(1):154–63. https://doi.org/10.1038/jid.2012.239.CrossRefPubMed

29.

Seki Y, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K, Komine O, Hamano S, Himeno K, Inagaki-Ohara K, Cacalano N, O'Garra A, Oshida T, Saito H, Johnston JA, Yoshimura A, Kubo M. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med. 2003;9(8):1047–54. https://doi.org/10.1038/nm896.CrossRefPubMed

30.

Goren I, Linke A, Muller E, Pfeilschifter J, Frank S. The suppressor of cytokine signaling-3 is upregulated in impaired skin repair: implications for keratinocyte proliferation. J Invest Dermatol. 2006;126(2):477–85. https://doi.org/10.1038/sj.jid.5700063.CrossRefPubMed

31.

Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005;6(4):328–40. https://doi.org/10.1038/nrm1619.CrossRefPubMed

32.

Omori-Miyake M, Yamashita M, Tsunemi Y, Kawashima M, Yagi J. In vitro assessment of IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice and humans. J Invest Dermatol. 2014;134(5):1342–50. https://doi.org/10.1038/jid.2013.503.CrossRefPubMed

33.

Wang Q, Gao S, Wu G-Z, Yang N, Zu X-P, Li W-C, Xie N, Zhang R-R, Li C-W, Hu Z-L, Zhang W-D. Total sesquiterpene lactones isolated from Inula helenium L. attenuates 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice. Phytomedicine. 2018;46:78–84. https://doi.org/10.1016/j.phymed.2018.04.036.CrossRefPubMed

Title: Igalan from Inula helenium (L.) suppresses the atopic dermatitis-like response in stimulated HaCaT keratinocytes via JAK/STAT3 signaling
Authors: Thien T. P. Dao
Kwangho Song
Jee Young Kim
Yeong Shik Kim
Publication date: 01-03-2020
Publisher: Springer International Publishing
Keyword: Atopic Dermatitis
Published in: Inflammation Research / Issue 3/2020
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-020-01322-4

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Crocin alleviates lipopolysaccharide-induced acute respiratory distress syndrome by protecting against glycocalyx damage and suppressing inflammatory signaling pathways

miR-425-5p improves inflammation and septic liver damage through negatively regulating the RIP1-mediated necroptosis

Thirty days after anterior cruciate ligament transection is sufficient to induce signs of knee osteoarthritis in rats: pain, functional impairment, and synovial inflammation

Tissue-resident memory T cells in the skin

Tachykinin-1 receptor antagonism suppresses substance-P- and compound 48/80-induced mast cell activation from rat mast cells expressing functional mas-related GPCR B3

lncRNA H19 sponging miR-93 to regulate inflammation in retinal epithelial cells under hyperglycemia via XBP1s

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage